Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Posts 2007 Net Loss of $2.4M

NEW YORK (GenomeWeb News) – Med BioGene reported today a 31.4 percent decrease its fiscal 2007 net loss.
The Vancouver, BC-based firm reported a net loss of $2.4 million, or $.09 per share, compared with a net loss of $3.5 million, or $.20 per share, for fiscal 2006. It said that the decrease was due to $2.3 million in charges in 2006 related to the acquisition of Dragon-Tex and the listing of its shares on the TSX Venture Exchange.
Med BioGene reported no revenues for full-year 2007. The firm is working on the development and commercialization of its LungExpress Dx gene expression prognostic assay for patients with early stage non-small cell lung cancer. It licensed exclusive, worldwide rights to the test last week from the Ontario-based University Health Network.
Med BioGene said that its R&D expenses more than doubled to $1.2 million from $565,168 in 2006, while its general and administrative costs also doubled to $1.2 million from $647,084 in 2006.
As of Dec. 31, Med BioGene had $1.4 million in cash and cash equivalents.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.